Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2010

01-06-2010 | Short Research Report

Community pharmacists’ views on adverse drug reactions reporting in Malaysia: a pilot study

Authors: Kang-Nee Ting, Dane Michael Stratton-Powell, Claire Anderson

Published in: International Journal of Clinical Pharmacy | Issue 3/2010

Login to get access

Abstract

Objectives To investigate community pharmacists’ knowledge, attitudes and views on adverse drug reaction (ADR) reporting. Setting Seven community pharmacies in Malaysia. Method Structured interviews with community pharmacists. Informed consent was obtained and interviews were audio-recorded and transcribed verbatim. Main Outcome Measures Content analysis of themes on awareness of ADR reporting, reporting activities, attitudes and views on patient reporting. Results All pharmacists claimed to have some knowledge of a reporting system but only one had submitted a report directly to the regulatory authority. Despite the low level of reporting activities, all participants agreed that it was part of their professional obligation to report an ADR. Most participants were not aware of the direct patient reporting scheme and were skeptical about its success. Lack of awareness and patients’ limited knowledge about their medications were viewed as barriers to patient reporting. Local attitudinal issues including pharmacists’ attitude towards ADR reporting were described as possible contributing factors. Conclusion Community pharmacists have an important role in reporting ADRs. Many Malaysian patients are still perceived to be ill-informed of their medications, an important determinant to the success of patient reporting. There is a need for further training about ADRs and ADR reporting for health professionals and further education for patients.
Literature
1.
go back to reference McEwen J. Risk management from an Asian/Pacific rim regulatory perspective. Drug Saf. 2004;27:491–7.CrossRefPubMed McEwen J. Risk management from an Asian/Pacific rim regulatory perspective. Drug Saf. 2004;27:491–7.CrossRefPubMed
2.
go back to reference Aziz Z, Siang TC, Badarudin NS. Reporting of adverse drug reactions: predictors of under-reporting in Malaysia. Pharmacoepidemiol Drug Saf. 2007;16:223–8.CrossRefPubMed Aziz Z, Siang TC, Badarudin NS. Reporting of adverse drug reactions: predictors of under-reporting in Malaysia. Pharmacoepidemiol Drug Saf. 2007;16:223–8.CrossRefPubMed
3.
go back to reference Ali SM, Harun H. Knowledge and attitudes of adverse drug reactions (ADRs) reporting among community pharmacists in Selangor, Malaysia. Pharm World Sci. Published online 9 May 2009. doi:10.1007/s11096-009-9298-8. Ali SM, Harun H. Knowledge and attitudes of adverse drug reactions (ADRs) reporting among community pharmacists in Selangor, Malaysia. Pharm World Sci. Published online 9 May 2009. doi:10.​1007/​s11096-009-9298-8.
4.
go back to reference van Grootheest K, de Graaf L, de Jong-van den Berg LTW. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf. 2003;26:211–7.CrossRefPubMed van Grootheest K, de Graaf L, de Jong-van den Berg LTW. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf. 2003;26:211–7.CrossRefPubMed
5.
go back to reference Consensus Document adopted at the First International Conference on CRM. Consumer reports on medicines—CRM: policy and practice. Int J Risk Saf Med. 2000;13:117–127. Consensus Document adopted at the First International Conference on CRM. Consumer reports on medicines—CRM: policy and practice. Int J Risk Saf Med. 2000;13:117–127.
6.
go back to reference Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2006;63:148–56.CrossRef Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2006;63:148–56.CrossRef
8.
go back to reference Belton KJ, The European Pharmacovigilance Research Group. Attitude survey of adverse drug reaction reporting by healthcare professionals across the European Union. Eur J Clin Pharmacol. 1997;52:423–7.CrossRefPubMed Belton KJ, The European Pharmacovigilance Research Group. Attitude survey of adverse drug reaction reporting by healthcare professionals across the European Union. Eur J Clin Pharmacol. 1997;52:423–7.CrossRefPubMed
9.
go back to reference Smith F. Research methods in pharmacy practice. London: Pharmaceutical Press; 2002. Smith F. Research methods in pharmacy practice. London: Pharmaceutical Press; 2002.
10.
go back to reference Fernandopulle RBM, Weerasuriya K. What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world. Drug Saf. 2003;26(4):219–25.CrossRefPubMed Fernandopulle RBM, Weerasuriya K. What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world. Drug Saf. 2003;26(4):219–25.CrossRefPubMed
Metadata
Title
Community pharmacists’ views on adverse drug reactions reporting in Malaysia: a pilot study
Authors
Kang-Nee Ting
Dane Michael Stratton-Powell
Claire Anderson
Publication date
01-06-2010
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 3/2010
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-010-9382-0

Other articles of this Issue 3/2010

International Journal of Clinical Pharmacy 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.